Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
The drug has also been shown to reduce the risk of heart attack, stroke, and death in those with cardiovascular disease by 20 percent
Clinical trial data show that injectable options slightly outperform oral options for weight loss, but real-world results vary by adherence and tolerability
A small crossover study (N=28) found that exenatide co-administration reduced levothyroxine Cmax by 16% without significantly changing AUC [13]
Patients reasonably ask: is this legit, or is it a workaround that could disappear
This can include adjusting dosages, combining multiple medications, or creating alternative formulations if you have allergies or sensitivities to certain ingredients